SRS Capital Advisors Inc. Raises Holdings in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

SRS Capital Advisors Inc. lifted its holdings in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 12.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,602 shares of the company’s stock after buying an additional 175 shares during the quarter. SRS Capital Advisors Inc.’s holdings in GE HealthCare Technologies were worth $125,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of GEHC. Farther Finance Advisors LLC boosted its position in shares of GE HealthCare Technologies by 10.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 4,520 shares of the company’s stock worth $424,000 after purchasing an additional 443 shares in the last quarter. Janney Montgomery Scott LLC acquired a new stake in shares of GE HealthCare Technologies in the third quarter valued at about $4,367,000. Intact Investment Management Inc. purchased a new stake in GE HealthCare Technologies during the third quarter worth about $73,000. National Pension Service grew its position in GE HealthCare Technologies by 15.8% during the third quarter. National Pension Service now owns 716,002 shares of the company’s stock worth $67,197,000 after buying an additional 97,826 shares during the period. Finally, Asset Management One Co. Ltd. increased its holdings in GE HealthCare Technologies by 0.9% in the third quarter. Asset Management One Co. Ltd. now owns 164,750 shares of the company’s stock valued at $15,462,000 after buying an additional 1,507 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Citigroup upped their price target on GE HealthCare Technologies from $103.00 to $110.00 and gave the stock a “buy” rating in a report on Thursday, February 13th. Wells Fargo & Company boosted their target price on GE HealthCare Technologies from $96.00 to $103.00 and gave the stock an “overweight” rating in a research report on Friday, February 14th. Finally, Jefferies Financial Group raised GE HealthCare Technologies from a “hold” rating to a “buy” rating and lifted their price target for the stock from $95.00 to $103.00 in a research note on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $97.67.

GE HealthCare Technologies Stock Performance

NASDAQ:GEHC opened at $84.76 on Thursday. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.04 and a quick ratio of 0.83. The firm has a market cap of $38.76 billion, a PE ratio of 19.58, a P/E/G ratio of 3.19 and a beta of 1.15. The firm has a 50 day simple moving average of $86.52 and a 200-day simple moving average of $86.13. GE HealthCare Technologies Inc. has a 1-year low of $74.51 and a 1-year high of $94.80.

GE HealthCare Technologies (NASDAQ:GEHC) last issued its quarterly earnings results on Thursday, February 13th. The company reported $1.45 earnings per share for the quarter, beating the consensus estimate of $1.26 by $0.19. GE HealthCare Technologies had a return on equity of 25.74% and a net margin of 10.13%. The company had revenue of $5.32 billion during the quarter, compared to the consensus estimate of $5.33 billion. On average, equities analysts expect that GE HealthCare Technologies Inc. will post 4.68 EPS for the current year.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.